Zealand Pharma A/S (ZLDPF)
USD 63.36
(0.57%)
USD 63.36
(0.57%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -658.89 Million DKK | 21.74% |
| 2022 | -665.26 Million DKK | 31.7% |
| 2021 | -711.85 Million DKK | -11.71% |
| 2020 | -627.94 Million DKK | -54.98% |
| 2019 | -562.63 Million DKK | 15.9% |
| 2018 | -442 Million DKK | -171.67% |
| 2017 | -246.27 Million DKK | -108.24% |
| 2016 | -118.26 Million DKK | -39.69% |
| 2015 | -81.24 Million DKK | -26.58% |
| 2014 | -64.54 Million DKK | 62.14% |
| 2013 | -177.68 Million DKK | -507.59% |
| 2012 | 41.91 Million DKK | 122.76% |
| 2011 | 14.68 Million DKK | 118.61% |
| 2010 | -104.57 Million DKK | -45.4% |
| 2009 | -76.24 Million DKK | -60.93% |
| 2008 | -44.68 Million DKK | 28.53% |
| 2007 | -62.52 Million DKK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -260.91 Million DKK | -5.12% |
| 2024 Q1 | -249.22 Million DKK | 9.23% |
| 2023 Q1 | -178.56 Million DKK | -6.66% |
| 2023 FY | - DKK | 21.74% |
| 2023 Q4 | -124.98 Million DKK | -268.05% |
| 2023 Q3 | 74.37 Million DKK | 141.1% |
| 2023 Q2 | -180.96 Million DKK | -1.34% |
| 2022 Q4 | -167.41 Million DKK | -16.78% |
| 2022 FY | - DKK | 31.7% |
| 2022 Q3 | -143.36 Million DKK | 48.92% |
| 2022 Q2 | -280.66 Million DKK | -290.27% |
| 2022 Q1 | -71.91 Million DKK | 75.29% |
| 2021 Q4 | -291.03 Million DKK | -37.41% |
| 2021 Q2 | -289.91 Million DKK | -11.12% |
| 2021 FY | - DKK | -11.71% |
| 2021 Q1 | -260.9 Million DKK | 23.84% |
| 2021 Q3 | -211.79 Million DKK | 26.95% |
| 2020 Q3 | -232.68 Million DKK | -351.55% |
| 2020 Q2 | -51.53 Million DKK | 70.92% |
| 2020 FY | - DKK | -54.98% |
| 2020 Q1 | -177.2 Million DKK | 10.83% |
| 2020 Q4 | -342.56 Million DKK | -47.22% |
| 2019 FY | - DKK | 15.9% |
| 2019 Q1 | -128.25 Million DKK | 21.57% |
| 2019 Q2 | -133.52 Million DKK | -4.11% |
| 2019 Q3 | -112.96 Million DKK | 15.4% |
| 2019 Q4 | -198.73 Million DKK | -75.93% |
| 2018 Q4 | -163.53 Million DKK | 46.13% |
| 2018 Q2 | -124.87 Million DKK | -54.85% |
| 2018 Q1 | -80.63 Million DKK | 35.39% |
| 2018 FY | - DKK | -171.67% |
| 2018 Q3 | -303.55 Million DKK | -143.1% |
| 2017 Q2 | -94.31 Million DKK | -3610.31% |
| 2017 FY | - DKK | -108.24% |
| 2017 Q4 | -124.8 Million DKK | -235.5% |
| 2017 Q3 | -37.19 Million DKK | 60.56% |
| 2017 Q1 | -2.54 Million DKK | -107.75% |
| 2016 Q1 | -63.95 Million DKK | -191.14% |
| 2016 Q4 | 32.81 Million DKK | 397.05% |
| 2016 Q3 | -11.04 Million DKK | 87.05% |
| 2016 Q2 | -85.32 Million DKK | -33.42% |
| 2016 FY | - DKK | -39.69% |
| 2015 Q2 | -64.56 Million DKK | -37.22% |
| 2015 Q4 | 70.17 Million DKK | 260.95% |
| 2015 FY | - DKK | -26.58% |
| 2015 Q1 | -47.05 Million DKK | 30.02% |
| 2015 Q3 | -43.6 Million DKK | 32.47% |
| 2014 Q3 | 15.62 Million DKK | 132.75% |
| 2014 Q4 | -67.23 Million DKK | -530.2% |
| 2014 FY | - DKK | 62.14% |
| 2014 Q1 | 28.86 Million DKK | 163.03% |
| 2014 Q2 | -47.72 Million DKK | -265.36% |
| 2013 FY | - DKK | -507.59% |
| 2013 Q4 | -45.79 Million DKK | -33.96% |
| 2013 Q3 | -34.18 Million DKK | 26.89% |
| 2013 Q2 | -46.75 Million DKK | 17.77% |
| 2013 Q1 | -56.86 Million DKK | -11.06% |
| 2012 Q2 | 23.76 Million DKK | -64.32% |
| 2012 Q1 | 66.59 Million DKK | 447.35% |
| 2012 FY | - DKK | 122.76% |
| 2012 Q4 | -51.19 Million DKK | -131179.49% |
| 2012 Q3 | -39 Thousand DKK | -100.16% |
| 2011 Q2 | 92.04 Million DKK | 324.83% |
| 2011 Q4 | -19.17 Million DKK | -59.54% |
| 2011 Q1 | -40.93 Million DKK | 34.65% |
| 2011 FY | - DKK | 118.61% |
| 2011 Q3 | -12.01 Million DKK | -113.06% |
| 2010 Q1 | -23.12 Million DKK | 0.0% |
| 2010 FY | - DKK | -45.4% |
| 2010 Q2 | 36.32 Million DKK | 257.08% |
| 2010 Q3 | -55.13 Million DKK | -251.76% |
| 2010 Q4 | -62.64 Million DKK | -13.62% |
| 2009 FY | - DKK | -60.93% |
| 2008 FY | - DKK | 28.53% |
| 2007 FY | - DKK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Evofem Biosciences, Inc. | -17.37 Million USD | -3693.27% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -16862.84% |
| CSL Limited | 4.78 Billion USD | 113.758% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 800.664% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -70223.038% |
| BioStem Technologies, Inc. | -7.55 Million USD | -8622.822% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -37550.936% |
| Qrons Inc. | -40.08 Thousand USD | -1643798.605% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 125024.114% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | -1090.645% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | -9100.75% |
| Skye Bioscience, Inc. | -13.54 Million USD | -4763.544% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -179326.286% |
| Rebus Holdings, Inc. | -951 Thousand USD | -69184.017% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -4051.871% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Genscript Biotech Corporation | -248.71 Million USD | -164.913% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -104087.974% |
| Adynxx, Inc. | - USD | Infinity% |
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | -827.545% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | -11013.191% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -275413.694% |
| SQZ Biotechnologies Company | -64.14 Million USD | -927.254% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -24816.013% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -42795.181% |
| Mesoblast Limited | -62.38 Million USD | -956.089% |
| Marizyme, Inc. | -34.28 Million USD | -1822.003% |
| Genus plc | 73.7 Million USD | 994.018% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | -9865.807% |
| Pharming Group N.V. | 9.87 Million USD | 6770.963% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -44197.814% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -18476.018% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | -7411.297% |
| ContraFect Corporation | -64.99 Million USD | -913.694% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -14457.283% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -46902.942% |
| IMV Inc. | -35.52 Million USD | -1754.809% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -28253.788% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -127087.74% |
| ONE Bio Corp. | 13.61 Million USD | 4940.144% |
| Accustem Sciences Inc. | -3.74 Million USD | -17487.221% |
| RVL Pharmaceuticals plc | -48.22 Million USD | -1266.228% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -51898.608% |
| Q BioMed Inc. | -617.62 Thousand USD | -106580.882% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 18545.997% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -28741.942% |
| Biomind Labs Inc. | -1.03 Million USD | -63588.718% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | -1562.319% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -22680.662% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 9799192.802% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -2635464.0% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -26234.972% |
| GB Sciences, Inc. | -1.41 Million USD | -46304.533% |
| Alpha Cognition Inc. | -9.7 Million USD | -6688.771% |
| HST Global, Inc. | -5303.00 USD | -12424772.714% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -31931.648% |
| Halberd Corporation | -74.27 Thousand USD | -886948.829% |
| Enzolytics Inc. | -2.12 Million USD | -30950.047% |
| Agentix Corp. | -1.37 Million USD | -47932.668% |
| Resverlogix Corp. | -11.74 Million USD | -5511.404% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -21411.184% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -216.02 Million USD | -205.01% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 54240.592% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 7541.9% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -43858.127% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 174021.456% |
| AVAX Technologies, Inc. | -6.11 Million USD | -10679.151% |
| Zenith Capital Corp. | -8.6 Million USD | -7556.182% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -3782065.203% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -26832.414% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -374218.077% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -34200.964% |
| Kadimastem Ltd | -2.62 Million USD | -25006.53% |
| Helix BioMedix, Inc. | -1.04 Million USD | -62872.708% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -363751.277% |
| LadRx Corporation | 412.28 Thousand USD | 159915.224% |
| Cell Source, Inc. | -4.27 Million USD | -15321.58% |
| Regen BioPharma, Inc. | 1.46 Million USD | 45046.165% |
| NovAccess Global Inc. | -1.03 Million USD | -63573.455% |
| Affymax, Inc. | -14.29 Million USD | -4509.241% |
| Itoco Inc. | -1.86 Million USD | -35153.759% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -173465.934% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -58940.412% |
| Mobile Lads Corp. | -2.24 Million USD | -29299.565% |
| CytoDyn Inc. | -18.02 Million USD | -3554.618% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -833633.187% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -5387838.507% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -135564.164% |
| SYBLEU INC | -141.57 Thousand USD | -465313.821% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -61941.883% |
| International Stem Cell Corporation | 202 Thousand USD | 326283.663% |
| Bioxytran, Inc. | -3.82 Million USD | -17147.792% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -1251592.629% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -26663.168% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | -1736.937% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -1464102.222% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -23964.682% |
| Neutra Corp. | -181.24 Thousand USD | -363432.086% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | -3168.471% |
| PureTech Health plc | -11.62 Million USD | -5566.905% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | -3168.695% |
| IXICO plc | -707 Thousand USD | -93095.332% |
| IntelGenx Technologies Corp. | -7.68 Million USD | -8473.728% |
| Gelesis Holdings, Inc. | -48.34 Million USD | -1262.866% |
| CSL Limited | 4.73 Billion USD | 113.921% |
| Cellectis S.A. | -92.63 Million USD | -611.269% |